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Background: Recent meta-analyses reported placebo response rate in antidepressant
trials to be stable since the 1970s. These meta-analyses however were limited in
considering only linear time trends, assessed trial-level covariates based on single-
model hypothesis testing only, and did not adjust for small-study effects (SSE), a well-
known but not yet formally assessed bias in antidepressant trials.
Methods: This secondary meta-analysis extends previous work by modeling nonlinear
time trends, assessing the relative importance of trial-level covariates using a multimodel
approach, and rigorously adjusting for SSE. Outcomes were placebo efficacy
(continuous), based on the Hamilton Depression Scale, and placebo response rate.
Results: Results suggested that any nonlinear time trends in both placebo efficacy
(continuous) and response rate were best explained by SSE. Adjusting for SSE revealed a
significant gradual increase in placebo efficacy (continuous) from 1979 to 2014. A similar
observation was made for placebo response rate, but did not reach significance due
higher susceptibility to SSE. By contrast, trial-level covariates alone were found to be
insufficient in explaining time trends.
Conclusion: The present findings contribute to the ongoing debate on antidepressant
placebo outcomes and highlight the need to adjust for bias introduced by SSE. The results
are of clinical relevance because SSE may affect the evaluation of success or failure in
antidepressant trials.
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HIGHLIGHTS
• Placebo time trends in antidepressant trials were examined between 1979 and 2014.
• Placebo efficacy (continuous) was found to gradually linearly increase across decades.
• Placebo response rate did not reach significance due to large small-study effects.
• Small-study effects explained large proportions of heterogeneity.
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• Trial-level covariates did not sufficiently explain
heterogeneity.
• Small-study effects may be considered when evaluating
success or failure in antidepressant trials.
INTRODUCTION
The term placebo effect is commonly used to designate symptom
relief due to a non-pharmacological intervention that cannot be
attributed to drug properties, and is therefore thought to reflect
patient expectations regarding that intervention (1). While it is
well-known that individuals receiving placebo in antidepressant
trials in major depressive disorder (MDD) can show substantial
improvement (2), there has been an ongoing debate whether this
placebo effect has been raising since the 1970s (3–10). This
debate is of clinical relevance because placebo effects have been
suspected to contribute to a decline in antidepressant treatment
effects, resulting in so-called failed antidepressant trials (3, 5, 6,
11–13).
Two recent meta-analyses conducted by Furukawa et al. (14,
15) disproved this hypothesis. The authors, who meta-
analytically examined N = 252 trials conducted between 1979
and 2016, reported that placebo response rate in antidepressant
trials have remained stable from 1979 to 2016. Any selective
improvement in placebo response was suggested to result from
trials conducted before 1991, at which year a structural break was
found, after which placebo response rate was reported to be (14).
The same conclusion was made by the authors based on a smaller
dataset comprising N = 98 trials conducted between 1985 and
2012 (15). To assess the effects of study year, Furukawa et al. (14,
15) splitted the data and computed linear regressions separately
before and after the observed structural break at 1991. Splitting
data for regression is however not advisable to account for the
likely nonlinearity underlying the structural break. The present
analysis therefore aimed to model the nonlinear time trend to
regress across the entire time span from 1979 to 2016. For this
purpose, the present analysis implemented restricted cubic
splines (RCS) (16), which are a powerful technique for
modeling nonlinear relationships using linear regression models.
Furukawa et al. (14, 15) further suggested that any potential
increase in placebo response rate before 1991 may be explained by
smaller mostly older studies showing larger treatment effects than
bigger studies. This phenomenon, known as small-study effect
(SSE) (17, 18) describes the association between sample size and
effect size in meta-analyses. To account for SSE, Furukawa et al.
(14, 15) adjusted the regression for sample size (defined as the
number of patients randomized). When adjusting for SSE,
however, there is actually a choice between a function of sample
size (or its inverse version) or a function of study precision
(variance, standard error, or their inverse versions), depending
on which one is more closely related to the sources of SSE. One
may argue that a function of sample size is the better covariate
because it does not experience measurement error or structural
correlation. However, as extensively studied by Moreno (19) a
function of precision is preferable since the sources of SSE have
increasingly been attributed to reasons such as publication bias,
outcome reporting bias, or clinical heterogeneity (20–22). A
function of study precision is therefore thought to be more
informative (23). The present analysis therefore aimed to
account for possible SSE by allowing placebo outcomes to
depend on the standard error (24, 25).
Moreover, Furukawa et al. (14, 15) suggested that the
potential increase in placebo response rate may also be
explained by changes in study designs across decades. The
authors therefore adjusted for the trial-level covariates study
center, study dosing schedule, and study length, which were
found to be significant. In particular, increasing placebo response
rate were suggested to be associated with shorter, single-centered
trials using flexible dose regimes before 1991 compared to longer,
multi-centered trails using fixed dose regimens mostly conducted
after 1991. The interpretation of these assumptions however
remained unclear; for example, it remained unclear why multi-
versus single-centered trials or fixed versus flexible dose regimes
would increase placebo effect sizes. The present analysis therefore
hypothesized that these trial-level covariate effects are mediated
effects (26) arising from insufficient adjustment for SSE across
decades. To assess the relative importance of trial-level covariates
effects before and after adjustment for SSE, multimodel inference
was conducted (27). Multimodel inference is an information
theoretic approach proposed as an alternative to traditional
single-model hypothesis testing as applied by Furukawa et al.
(14, 15). Multimodel inference examines several competing
hypotheses (models) simultaneously to identify the best set of
models via information criteria such as the Akaike’s information
criterion (28), and is thus thought to provide more robust
covariate estimates (27).
Last, Furukawa et al. (14, 15) estimated placebo response rate
(defined as ≥50% reduction on the HAMD) based on the
proportion of responders within placebo groups. In the second
meta-analysis (15) the authors additionally assessed the
original continuous outcome, i.e., symptom reduction (29)
based on the Hamilton Depression Scale (HAMD) (30), from
which the binary outcome (response rate) is derived through
dichotomization. The continuous outcome was estimated based
on the drug-placebo difference between drug and placebo groups.
The authors did, however, not consider symptom reduction
within placebo groups, which would be the logical equivalent
to placebo response rate. The present analysis therefore aimed to
extend previous work by examining symptom reduction within
placebo groups estimated based on the pre-post change on the
HAMD within placebo groups, hereinafter referred to as
efficacy (continuous).
Together, the methodological approach presented here aimed
to support the ongoing debate on placebo outcomes across
decades by considering nonlinear time trends, adjusting for
SSE, assessing the relative importance of trial-level covariates,
and comparing the binary with the original continuous placebo
outcome. The results are expected to inform clinical decision
making whether time trends may require consideration when
evaluating success or failure in antidepressant trials in MDD.
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MATERIALS AND METHODS
Data Sources
A total of 308 randomized placebo-controlled trials (240
published studies, 68 unpublished studies) were identified
conducted between 1979 and 2016. Three hundred four trials
constituted all the placebo-controlled trials provided in the
GRISELDA dataset by Cipriani et al. (31) and four additional
trials were provided by Furukawa et al. (14). For all studies,
information on the year of completion was extracted from the
literature, if available. For 30 studies, missing covariate values
were extracted from the literature. A PRISMA (Preferred
Reporting Items for Systematic Reviews and Meta-Analyses)
flow-chart detailing the study selection process is given in the
supplementary appendix (Supplementary S1).
Covariate study year was defined as study year of completion,
study year of publication, or year of drug approval from the FDA
(US Food and Drug Administration), where available in this
order; preference was given to study year of completion, because
unpublished trials, by definition, have no year of publication
(14). The resulting study year range was 1979–2014. Other trial-
level covariates were study center (multi- versus single-center),
study dosing schedule (flexible versus fixed dose), study length
(range 4–12 weeks), and study size (sample size, number of
patients randomized) (14).
Primary continuous outcome was efficacy (continuous) (pre-
post change on the HAMD, i.e., endpoint HAMD or, if not
reported, change from baseline HAMD, as provided in the
GRISELDA dataset (31), N = 259 trials) within placebo groups,
estimated as log-transformed change score. Primary binary
outcome was response rate (≥50% reduction on the HAMD,
N = 277 trials), estimated as log-transformed proportions of
responders within placebo groups. Remission rate was not
assessed because different cut-offs (<7 or <8 total reduction on
the HAMD) were used for aggregation, which can be
problematic when analyzing only within groups.
Structural Break Analysis
To assess potential breaks across study year, a structural break
analysis was conducted using the breakpoints command in the
strucchange package (32) in R (33). To capture potential
structural breaks in the meta-regression, the covariate study
year was modeled using RCS (16) by use of the command rcs
in the rms package (34). RCS were constructed using three knots
with the middle knots set at the break date, and the first and third
knots set at the 10th and 90th percentile of study year, i.e., (1986,
break date, 2010).
Adjustment for Small-Study Effects
To adjust for SSE, limit meta-analysis was conducted using the
metasens package (35) (Supplementary S4). Limit meta-analysis
is a regression approach based on an extended random-effects
model that takes account of possible SSE by allowing trial
estimates to depend on the standard error (24, 25, 36). The
resulting adjusted (“shrunken”) trial estimates obtained from the
limit meta-analysis were then used for further analysis.
Heterogeneity that remains after SSE are accounted for can be
quantified by the heterogeneity statistic G2 (24, 25).
To graphically visualize potential SSE, the power of individual
studies was computed based on its standard errors using a two-
sided Wald test, together with a test assessing potential excess of
formally significant trials in relation to the power (37) as
implemented in the metaviz package (38). The test itself does
not consider SSE but can have similar sources.
Multimodel Inference
Multimodel inference was conducted using the glmulti package
(39) that provides the necessary functionality for multimodel
averaging using an information-theoretic approach. An extensive
model comparison was conducted considering all possible
covariate combinations. Multimodel inference was performed
both before and after adjustment for SSE based on the limit
meta-analysis. The only constraint was that the nonlinear
component of study year was only included in the presence of
the linear component, since the former alone is uninterpretable.
Together this resulted in N = 47 models. Model weighting was
based on the corrected Akaike information criterion (AICc), with
each model being weighted based on relative AICc evidence (39).
Multimodel averaged covariate estimates were computed across
the top model sets for each outcome, defined as the top-ranked
models summing up to 95% AICc evidence weight (27, 40).
Models were fitted using the rma function in the metafor package
(41). Heterogeneity was estimated based on the method of
moment (42) and reported in terms of t2 and I2.
RESULTS
Structural Break Analysis
Structural break analysis revealed no break date for placebo
efficacy (continuous) (F = 3·09, p = 0·139), suggesting a gradual
increasing trend from 1979 to 2014. By contrast, a break date was
found at 1990 for placebo response (F = 11·45, p < 0·001),
suggesting a steep nonlinear increase around 1990; in line with
Furukawa et al. (14) (see Supplementary S2 for illustration of the
structural break analysis). To assess the potential nonlinear trend
across decades, the break date at 1990 was used to construct the
nonlinear component of the covariate study year used in the
multimodel inference (see Supplementary S3 for sensitivity
analysis on the nonlinear component).
Multimodel Averaged Covariate Effects
Overall, results suggested both placebo efficacy (continuous) and
response rate to be affected by SSE. Adjustment for SSE weakened
the effect of study year in both outcomes. However, the linear effect of
study year indicated by the structural break analysis remained
significant for efficacy (continuous) [linear b = −0·07 (−0·12 to
−0·02) 95% CI; nonlinear b = 0·00 (−0·02 to 0·02) 95% CI]
(Table 1, Figure 1). This supported a gradual increase in placebo
efficacy (continuous) across decades from 1979 to 2014, that is not
explained by SSE. By contrast, both linear and nonlinear components
of study year became insignificant for placebo response due to wide
Holper Placebo Effects Across Decades
Frontiers in Psychiatry | www.frontiersin.org July 2020 | Volume 11 | Article 6333
CIs [linear b = 0·07 (−0Â·05 to 0·18) 95% CI; nonlinear b = −0·05
(−0·14 to 0·05) 95% CI] (Table 1, Figure 2). Together, this suggested
that the binary outcome was more affected by SSE, with lower study
precision observed in older and smaller studies before 1991 compared
to studies conducted after 1990.Among the other trial-level covariates
only study center revealed significant effects in both outcomes.
However, supporting our hypothesis of possible mediated effects,
any effects of study center became nearly zero after adjusting for SSE
(Table 2). None of the remaining trial-level covariates were found to
have significant effects (see Supplementary S5 for details on relative
covariate importance). Together, this suggested that trial-level
covariates alone were insufficient in explaining placebo outcomes.
To graphically visualize the suggested SSE, the power of
individual studies was illustrated in Figures 1 and 2. The
power distributions show that most of the trials estimates for
efficacy (continuous) were high-powered (0Â·4% low power, 8%
adequate power, 91% high power) with no excess of significant
trials (p = 0·236), whereas placebo response rate was
underpowered (13% low power, 70% adequate power, 17%
high power) with an excess of significant trials (p = 0·001) (see
Supplementary S4 for funnel. plots derived from limit meta-
analysis compared to power-enhanced funnel plots). Together,
this supported the assumption that placebo response rate was
more affected by SSE than placebo efficacy (continuous).
Multimodel Averaged Heterogeneity
Since, it is well-known that I2 has undue reliance due to its
dependence on precision (43, 44), it is an improper measure
when comparing continuous and binary outcomes because the
former result in systematically higher I2 (45). t2, rather than I2, is
therefore suggested the appropriate measure for this purpose as it is
insensitive to study precision (43) (Table 2). Comparing between
outcomes suggested an overall equal reduction in heterogeneity
(efficacy (continuous) = −13%, response rate = −12%) when SSE
were not accounted for. However, when accounting for SSE, a
much larger reduction in heterogeneity was observed for response
rate (−70%) compared to efficacy (continuous) (−37%). Again, this
supported the assumption of larger SSE in the binary compared to
the continuous outcome.
Heterogeneity was also assessed in terms of G2 derived from
the limit meta-analysis. G2 represents heterogeneity that remains
after SSE are accounted for. Likewise I2, G2 is determined on a
percentage scale, but not dependent on study precision and thus
appropriate for comparison between outcomes (25, 43). Whereas
G2 was almost zero for placebo efficacy (continuous) (G2 = 2%),
it was G2 = 24% for placebo response rate. This indicated that
efficacy (continuous) approximated the case of G2 = 0 while > 0,
that is, there is not much other heterogeneity apart from that due
to SSE (to which is sensitive but not G2) (25) (Table 2, see
Supplementary S4 for details on the limi meta-analysis).
Together, this suggested that efficacy (continuous) was almost
fully explained by SSE, whereas placebo response rate remained
with some unexplained heterogeneity even after adjustment
for SSE.
DISCUSSION
Selective improvements in placebo effects can significantly
affect the success or failure of antidepressant trials. Declining
antidepressant efficacy across decades has been previously
suggested due to increasing placebo efficacy, resulting in so-
called failed antidepressant trials (3, 5, 6, 11–13). Study year has
been suggested to be the second greatest effect modifier in
antidepressant efficacy as reported by Cipriani et al. (31), but
this itself does not inform about why outcomes are heterogeneous
TABLE 1 | Multimodel averaged covariate estimates.
Efficacy (cont.) Response
Model year only b (95% CI) b (95% CI)
Year linear −0.21 (−0.34 to −0.07) 0.39 (0.25 to 0.53)
Year nonlinear 0.09 (−0.03 to 0.21) −00.28 (−0.41 to −00.16)
Multimodel b (95% CI) W b (95% CI) W
Year linear −0.10 (−0.14 to −00.05) 1.0 0.26 (0.12 to 0.40) 1.0
Year nonlinear 0.01 (−0.01 to 0.02) 0.1 −00.19 (−0.32 to −00.07) 1.0
Center −0.20 (−0.30 to −00.10) 1.0 0.28 (0.18 to 0.37) 1.0
Dosing −0.01 (−0.06 to 0.03) 0.5 0.01 (−0.03 to 0.05) 0.3
Length 0.00 (−0.01 to 0.01) 0.3 0.02 (−0.02 to 0.06) 0.7
Size 0.00 (−0.01 to 0.01) 0.2 −00.01 (−0.03 to 0.02) 0.4
Multimodel (SSE) b (95% CI) W b (95% CI) W
Year linear −00.07 (−0.12 to −00.02) 1.0 0.07 (−0.05 to 0.18) 0.8
Year nonlinear 0.00 (−0.02 to 0.02) 0.2 −00.05 (−0.14 to 0.05) 0.6
Center −00.00 (−0.02 to 0.01) 0.1 0.01 (−0.03 to 0.05) 0.3
Dosing 0.00 (−0.02 to 0.02) 0.3 0.00 (−0.01 to 0.02) 0.2
Length 0.00 (−0.01 to 0.01) 0.3 0.02 (−0.01 to 0.05) 0.8
Size 0.02 (−0.01 to 0.05) 0.7 −00.05 (−0.08 to 0.02) 1.0
Listed are standardized covariate estimates (95% confidence intervals, CI) for the model adjusted for year only and the multimodel average before and after accounting for small-study
effects (SSE). The relative covariate importance is given in terms of AICc evidence weights (W), with larger values indicting greater importance, whereas values near zero indicate that there
is little or no evidence that the given covariate of interest explains variation in the corresponding outcomes. Significant effects (p < 0·05) are highlighted (red).
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across years. It is therefore of clinical relevance to explore the
reasons of potentially increasing placebo effects across decades.
Furukawa et al. (14, 15) suggested that any potential secular
changes in placebo outcomes may be explained by changes in
study designs corresponding to differences in study centers, study
dosing schedule, study length, or study size. The present findings
rather suggest that small-study effects drive most of the changes in
placebo outcomes across decades, due to older mostly smaller
antidepressant trials being greatly underpowered. This assumption
is in line with previous work, suggesting fundamental flaws in
antidepressant trials due to underpowered effects sizes and a lack
of precision in depression outcome measurements for the past 40
years (46).
The present findings show that adjusting for these small-
study bias largely reduces heterogeneity and removes any
nonlinear effects of study year. Still, a remaining linear trend is
suggested for efficacy (continuous) gradually increasing from
1979 to 2014, that is not explained by small-study effects. This
increasing trend does not seem to follow a structural break as
suggested by Furukawa et al. (14, 15), again disproving any
underlying nonlinearity. Considering the low heterogeneity that
remained after small-study effects were accounted for (G2 = 3%),
suggests that further bias adjustments may not essentially change
these findings.
By contrast, trial-level covariates alone were found to be
insufficient in explaining placebo time trends and may even led
to misleading conclusions by Furukawa et al. (14, 15). The
present work rather suggests that at least part of the trial-level
covariate effects may be mediated by small-study effects without
having own effects. An example is the effect of study center that
was found to be insignificant after adjusting for small-study
effects. This is likely a result of the close relation between secular
changes from single-centered trials with small sample size (and
thus low study precision) in older trials, versus more multi-
centered trials with larger sample sizes (and thus higher study
precision) in more recent trials. This illustrates the importance of
adjusting for small-study effects in order to derive reliable trial-
level covariate effects in antidepressant trials.
The observed differences between the continuous and binary
outcomes are likely a result of the dichotomization of the original
HAMD scale. In clinical practice, dichotomization is sometimes
justified to label groups of individuals with diagnostic or
therapeutic attributes (47, 48). However, methodologists have
advised against the use of dichotomization because it reduces
FIGURE 1 | Efficacy (continuous). Meta-regression plot illustrating the effect of study year on placebo efficacy (continuous) for the model adjusted for year only and
the multimodel average considering both main and interaction effects, before and after accounting for small-study effects (SSE). Values larger on the log-transformed
change score scale indicate increase in efficacy (continuous). Circle size is proportional to study size. Circle color is proportional to the power of individual studies
(100% high power [white], 100-80% adequate power [light gray], <80% low power [dark gray]). Slopes are illustrated at the means of all covariates.
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statistical power and inflates effect sizes (49–52). To derive binary
constructs, the quantitative HAMD scale is dichotomized along
arbitrary cut-off scores (49, 51, 53, 54). This can create artificial
boundaries, were patients just below and above the cut-off fall into
different binary (49). For example, a responder, who drops 50%
from 40 to 20 on the HAMD can still be quite depressed, while
someone who drops from 20 to 10 is almost in remission.
Compared with efficacy (continuous), response rates are thus
less precise since most of the information distinguishing patients
on the original scale is lost (52).
These aspects are even more problematic considering small
sample sizes, because the reduction in statistical power
consequently requires larger sample sizes in binary outcomes
to be adequately powered (55). Although, there are no clear
sample size requirements for meta-analyses, previous work
showed that small trials (e.g., fewer than 50 patients) can
FIGURE 2 | Response rate. Meta-regression plot illustrating the effect of study year on placebo response rate. Shown are the model adjusted for year only and the
multimodel average considering both main and interaction effects, before and after accounting for small-study effects (SSE). Values smaller on the log-transformed
proportion scale indicate increase in response rate. Circle size is proportional to study size. Circle color is proportional to the power of individual studies (100% high
power [white], 100-80% adequate power [light gray], <80% low power [dark gray]). Slopes are illustrated at the means of all covariates.
TABLE 2 | Multimodel averaged heterogeneity statistics.
Efficacy (cont.) t2(%) I2 G2
Model year only 0.0456 (−13%) 88%
Multimodel 0.0449 (−15%) 88%
Multimodel (SSE) 0.0282 (−46%) 82% 3%
Response t2(%) I2 G2
Model year only 0.0386 (−12%) 71%
Multimodel 0.0377 (−13%) 71%
Multimodel (SSE) 0.0141 (−68%) 47% 24%
Listed are heterogeneity statistics for the model adjusted for year only and the multimodel average considering both main and interaction effects, before and after accounting for small-study
effects (SSE), in terms of t2 [with the percentage reduction (%) compared to the unadjusted model] and I2. Listed is also the heterogeneity statistic G2 (scaled 0–100%) derived from the limit
meta-analysis, interpreted as the proportion of unexplained heterogeneity after accounting for SSE.
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produce 10–48% larger binary estimates than larger trials (56).
Most trials completed before 1990 had on average less than 50
patients. As a consequence, the power of the binary outcome was
reduced before 1990. This is because the precision of the binary
outcome is statistically dependent on its effect estimate. This
dependence induces a well-known asymmetry in funnel plots, a
sort of mathematical artifact (57, 58), which also explains the
steep nonlinear trend suggested by the break analysis. As a
consequence, placebo response rate showed (59). The present
findings thus provide another example that response rate in
antidepressant trials may generally be avoided due to low
statistical power and spuriously inflated effect sizes. The
continuous outcome may be preferred when available, which is
viewed as a more favorable endpoint as it is less susceptible to
small-study effects.
Limiting the present analysis is the fact that the described
phenomena of underpowered effect sizes and small-study effects
can cause similar results besides having different reasons.
Interpretation should therefore be cautious, given that it is not
possible to separate the different mechanisms of bias (37, 60).
Another possible and probably the most well-known reason for
small-study effects is publication bias, which occurs when the
chance of smaller studies being published is increased when
having significant positive results, compared to larger studies
which may be accepted and published regardless. Notably,
publication bias can also arise from time-lag effects, resulting
from the variability in the time it takes to complete and publish a
study (61). Weak or negative results have been shown to take
approximately two to three more years to be published compared
to stronger and positive results (62, 63). To reduce the
implications of potential time-lag effects (and to allow for the
inclusion of non-published studies), the present analysis
therefore synthesized results across completion years, if
available. Other well-known causes of small-study effects are
outcome selection bias, where only favorable outcomes are
selectively reported (20, 64, 65), and clinical heterogeneity, e.g.,
patients in smaller studies may have been selected so that a
favorable outcome is to be expected (59), both of which are not
addressed in the present analysis.
Another limitation of the present analysis is that it did not
separately address risk of bias (RoB) and how this relates to SSE,
because it is difficult to relate RoB only to placebo outcomes
without consideration of the drug-related RoB. The funnel plots
and Egger’s test as detailed in the supplementary appendix
(Supplementary S4), however, give at least some quantification
of RoB related to the presence of possible publication bias. For a
detailed assessment of RoB of the included studies it is referred to
Cipriani et al. cipriani (31).
Further research may be required to explain the reasons for
the observed increase in placebo efficacy (continuous) across
decades. Earlier meta-analyses considered several other trial-
level or patient characteristics, such as the use of placebo run-in,
probability of being allocated to placebo, number of trial arms,
publication status, co-medication, country region, primary
versus secondary care, inpatient versus outpatient settings, age,
sex, and baseline depression severity (3, 5, 7, 9, 14, 66–70); none
of which consistently explained placebo outcomes. Based on the
extensive previous work, it therefore seems unlikely that other
trial-level or patient characteristics can fully explain the present
observations. One might therefore also consider factors other
than measurable covariates. For example, it has been suggested
that marketing has led to an increased public perception that
antidepressants are effective. This may increase the consumer
demand for the thus advertised antidepressants, and may create
conditioned responses and expectations that can produce a
placebo effect similar to that when the medication is taken (71,
72). Others have argued that inter-rater and intra-rater
variabilities contributed to this phenomenon (73–75). Again,
others suggested that the issue of unblinded outcome-assessors
in double-blind trials has led to worse placebo outcomes in older
compared to more recent trials due to the older drugs’ marked
side effects compared to newer generation antidepressants (76).
All these aspects may also be related to overall higher standards
in trial conductance by pharmaceutical companies in more
recent trials, which not only significantly increased sample
sizes, but may have also increased expectations in placebo
receiving individuals (46).
In conclusion, there has been an ongoing debate how placebo
outcomes in antidepressant trials can be explained across
decades. The present analysis aimed to contribute to the debate
suggesting that secular changes in placebo outcomes are best
explained by small-study effects, rather than by trial-level
covariates. Further research may be required to adjust the
corresponding antidepressant treatment effects for small-study
effects, to account for increase in placebo efficacy (continuous).
This is of clinical relevance to evaluate success or failure in
antidepressant trials.
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64. Chan AW, Hróbjartsson A, Haahr MT, Gøtzsche PC, Altman DG. Empirical
Evidence for Selective Reporting of Outcomes in Randomized
TrialsComparison of Protocols to Published Articles. JAMA (2004)
291:2457–65. doi: 10.1001/jama.291.20.2457
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